Secondary endpoints include assessment of promptly without troublesome dyskinesia and decrease in fatigue. Adamas expects the scholarly research to end up being completed in 2012. Dr. Of additional importance, if this study is successful, we will confirm our capability to research LID and pave just how for potential innovations reliably. .. Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson’s disease Adamas Pharmaceuticals, Inc., a held company privately, announced today that it offers initiated a Phase 2/3 clinical trial of its proprietary investigational drug Advertisements-5102 for the treating levodopa induced dyskinesia in patients with Parkinson’s disease.Alliqua announced the successful completion of its dissolution study previously. In the comparative in vitro permeation study, the Alliqua patch demonstrated mean cumulative medication permeation that was competitive with the marketplace leading product for the treatment of pain connected with post-herpetic neuralgia or shingles, a rising medical problem in the United States and all over the world as countries continue to have a problem with significantly elderly populations.